Physician profile
Patrick Lynn Boler
NPI 1225390719
$44,483.33
in general payments reported to CMS, 2019-2025
41 companies · $30K in 2025
The $30K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,565 · 2020: $1,121 · 2021: $1,982 · 2022: $2,831 · 2023: $2,847 · 2024: $3,768 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $9,939 · Consulting Fee: $695 · Travel and Lodging: $346 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,800.00 |
| Food and Beverage | $9,938.95 |
| Consulting Fee | $695.00 |
| Travel and Lodging | $345.80 |
| Education | $204.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $27,365.32 | 2019-2025 | Nemluvio, Epsolay, Aklief |
| Abbvie INC. | $3,138.85 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $2,356.84 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,441.41 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,140.87 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $1,006.08 | 2020-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $967.85 | 2021-2025 | Opzelura |
| Pfizer INC. | $900.90 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $793.82 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $690.64 | 2019-2025 | Adbry, Anzupgo |
| Almirall LLC | $660.46 | 2019-2025 | Seysara, Klisyri |
| Lilly USA, LLC | $636.21 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $423.74 | 2019-2024 | Arazlo, Cabtreo, Siliq |
| Genzyme Corporation | $402.69 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $263.94 | 2019-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Boler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.